.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 8,106,029

« Back to Dashboard

Claims for Patent: 8,106,029

Title:Use of A.sub.2A adenosine receptor agonists
Abstract: Myocardial imaging methods are provided that are accomplished by administering doses of a pharmaceutical composition comprising one or more adenosine A.sub.2A receptor agonists, in particular regadenoson, useful for, among other indications, myocardial imaging and coronary vasodilation, in an amount sufficient to achieve at least a minimal increase in average coronary peak flow velocity.
Inventor(s): Gordi; Toufigh (Sunnyvale, CA), Olmsted; Ann Walls (Palo Alto, CA), Lieu; Hsiao Dee (Burlingame, CA), Belardinelli; Luiz (Palo Alto, CA)
Assignee: Gilead Sciences, Inc. (Foster City, CA)
Application Number:12/637,583
Patent Claims: 1. A method of producing coronary vasodilation in a human in need thereof comprising administering to the human a single intravenous (iv) bolus dose of a pharmaceutical composition comprising: a) regadenoson, a compound named (1-{9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-aminop- urin-2-yl}pyrazol-4-yl)-N-methylcarboxamide, which has the formula: ##STR00002## and b) at least one pharmaceutical excipient wherein the composition has a pH of from about 6 to about 8; wherein the single dose of the pharmaceutical composition is administered in an amount that is sufficient to increase the average coronary peak flow velocity by at least about 16.5 cm/sec to about 105 cm/sec.

2. The method of claim 1, wherein the single dose of the pharmaceutical composition further comprises a member selected from the group consisting of water, distilled water, de-ionized water, saline, buffer solutions, normal isotonic saline solution, dextrose in water, and combinations thereof.

3. The method of claim 2, wherein the single dose of the pharmaceutical composition further comprises a buffer solution and the buffer is selected from the group consisting of dibasic sodium phosphate, dibasic sodium phosphate dehydrate, monobasic sodium phosphate monohydrate, and combinations thereof.

4. The method of claim 3, wherein the buffer is dibasic sodium phosphate and monobasic sodium phosphate monohydrate.

5. The method of claim 4, wherein the single dose of the pharmaceutical composition further comprises EDTA.

6. The method of claim 5, wherein the single dose of the pharmaceutical composition further comprises propylene glycol in an amount from about 5% to about 25% (w:v).

7. The method of claim 6, wherein the propylene glycol is present in an amount from about 8% to about 20% (w:v).

8. The method of claim 7, wherein the single dose of the pharmaceutical composition comprises from about 10 to about 500 micrograms of regadenoson.

9. The method of claim 8, wherein the single dose of the pharmaceutical composition comprises from about 0.05 to about 60 .mu.g/kg of regadenoson.

10. The method of claim 1, wherein the single dose of the pharmaceutical composition is administered in about 10 to about 20 seconds.

11. The method of claim 1, wherein the amount of the single dose of the pharmaceutical composition is sufficient to raise the average coronary peak flow velocity by an amount ranging from about 16.5 to about 77.0 cm/sec.

12. A method of performing myocardial perfusion imaging of a human in need thereof, said method comprising: 1) administering to the human a single intravenous (iv) bolus dose of a pharmaceutical composition comprising: a) regadenoson, a compound named (1-{9-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-aminop- urin-2-yl}pyrazol-4-yl)-N-methylcarboxamide, which has the formula: ##STR00003## and b) at least one pharmaceutical excipient wherein the composition has a pH of from about 6 to about 8; wherein the single dose of the pharmaceutical composition is administered in an amount that is sufficient to increase the average coronary peak flow velocity by at least about 16.5 cm/sec to about 105 cm/sec; 2) administering at least one radionuclide; and 3) imaging the myocardium of the human, wherein said imaging is conducted at least concomitantly with process steps 1 and 2.

13. The method of claim 12, wherein the single dose of the pharmaceutical composition and the radionuclide are administered to the human simultaneously.

14. The method of claim 12, wherein the single dose of the pharmaceutical composition and the radionuclide are administered to the human separately.

15. The method of claim 12, wherein the myocardium imaging begins no sooner than about 1 minute from the time the single dose of the pharmaceutical composition is administered to the human.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc